CHEMICAL-SYNTHETIC in APAC
INA Pharmaceuticals Pvt. Ltd. (INA Pharma) is a research-driven pharmaceutical organization based in Hyderabad, India, engaged in delivering advanced Discovery, Contract Development, and...
About the plant
INA Pharmaceuticals operates a state-of-the-art manufacturing and R&D facility designed to support complex chemical process development and large-scale production of pharmaceutical intermediates and specialty chemicals.
The plant is equipped with modern pilot and commercial-scale reactors, ranging from 0.5 KL to 3 KL, constructed with both stainless steel and glass-lined materials to handle diverse chemistries. A dedicated hydrogenation facility with reactor capacities from 10 L to 1 KL enables safe and efficient execution of high-pressure reactions.
The facility includes a well-developed kilo lab and scale-up unit with 50 L to 200 L glass assemblies, supporting seamless transition from laboratory development to pilot-scale manufacturing. Advanced column purification systems allow processing at multi-kilogram levels, ensuring high product purity.
INA Pharmaceuticals maintains integrated drying and packaging units, ensuring efficient downstream processing and readiness for dispatch. The plant is supported by well-equipped Quality Control laboratories featuring advanced analytical instruments to ensure strict adherence to quality and regulatory standards.
From an environmental and safety standpoint, the site is equipped with double-stage scrubber systems for effective emission control. The facility currently operates with an electrical boiler system, with plans to transition to a CNG-based system to enhance energy efficiency and sustainability.
Overall, the plant is designed to deliver safe, scalable, and compliant manufacturing, supporting the needs of global pharmaceutical and specialty chemical partners.
Compliance
- ICH
- ISO
- 9001
- 14001
- 45001
- ICHQ1A
Activity
- CHEMICAL-SYNTHETIC, RSM (Raw Starting Materials), Intermediates, Fine Chemicals, Excipients manufacturing
Features
- Uses: Commercial (Phase IV), Human
- Toxicity (OEB classification): N/A
- Controlled substance: N/A
- BSL: N/A
- Therapeutic areas: N/A
- Markets: FDA (USA), PMDA (Japan), NMPA (China), EDE (UAE), SFDA (Saudi Arabia)
Batch Size / Reactor
- Medium, > 10,000 L
Services
- Development services, Manufacturing services, QbD (Quality by Design), Process development, Process optimization, Process validation, Stability studies design, Stability studies execution, ICH Stability studies, Comparability studies, Tech transfer, Pilot plant, Research batches, Scale-up, Pilot batches, Batch records, Milling, Safety studies, Solid form selection, Nitrosamine risk assessment, Customized block synthesis
